Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multi-centric Castleman's Disease 2Sarcoma, Kaposi 1Neoplasms 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma 1Lymphadenopathy 1HIV Infections 1Castleman Disease 1Acquired Immunodeficiency Syndrome 1

Interventions

Cyclophosphamide 62Vincristine 45Doxorubicin 43Etoposide 42Rituximab 37Prednisone 31Filgrastim 31Biopsy 27Peripheral Blood Stem Cell Transplantation 25Cytarabine 24Radiotherapy 22fludarabine phosphate 19Specimen Handling 19Methotrexate 19Magnetic Resonance Spectroscopy 18Prednisolone 17Melphalan 16Ifosfamide 14Dexamethasone 14Bleomycin 13Leucovorin 12Cyclosporine 12Carmustine 12sargramostim 11Cisplatin 10Vinblastine 8Chlorambucil 8Busulfan 8fludarabine 7Nivolumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma × Valganciclovir × Clear all
NCT00217503 2013-06-20

Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
15 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡